Stifel Financial Corp Invests $52,000 in 908 Devices Inc. (NASDAQ:MASS)

Stifel Financial Corp acquired a new stake in shares of 908 Devices Inc. (NASDAQ:MASS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 23,509 shares of the company’s stock, valued at approximately $52,000. Stifel Financial Corp owned about 0.07% of 908 Devices at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Marshall Wace LLP acquired a new stake in 908 Devices in the 4th quarter valued at $85,000. XTX Topco Ltd bought a new stake in shares of 908 Devices during the fourth quarter worth $115,000. Bank of Montreal Can bought a new stake in 908 Devices in the fourth quarter valued at about $124,000. Geode Capital Management LLC increased its holdings in 908 Devices by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 581,300 shares of the company’s stock valued at $1,279,000 after purchasing an additional 13,512 shares during the last quarter. Finally, Prudential Financial Inc. bought a new stake in 908 Devices in the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

908 Devices Stock Performance

MASS stock opened at $4.58 on Friday. The company has a market capitalization of $163.69 million, a P/E ratio of -2.59 and a beta of 0.26. 908 Devices Inc. has a 52-week low of $1.81 and a 52-week high of $7.03. The business has a 50-day simple moving average of $4.60 and a two-hundred day simple moving average of $3.27.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%. The company had revenue of $11.78 million for the quarter, compared to analysts’ expectations of $11.90 million. As a group, sell-side analysts forecast that 908 Devices Inc. will post -1.99 earnings per share for the current fiscal year.

Insider Buying and Selling at 908 Devices

In related news, Director Mark Spoto acquired 10,000 shares of the stock in a transaction on Wednesday, May 14th. The stock was acquired at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the acquisition, the director now directly owns 62,971 shares of the company’s stock, valued at approximately $270,145.59. This represents a 18.88% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 27.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a research report on Saturday, May 10th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.33.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.